Locally Advanced/Metastatic Solid Tumors Clinical Trial
Official title:
A Phase 1, Open-Label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Preliminary Efficacy of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors
The study has consists of two parts, a dose escalation part (Part 1) and a dose selection optimization part (Part 2). The primary objectives of this study are to evaluate the safety and tolerability of ISM3412 in participants with locally advanced/metastatic solid tumors, and to determine the RP2D of ISM3412.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05801237 -
PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT06130722 -
First-in-Human, Phase I, Open-label, Multicenter, Dose Escalation Clinical Study
|
Phase 1 | |
| Completed |
NCT04914351 -
HY-0102 Monotherapy in Patients With Locally Advanced/Metastatic Solid Tumours
|
Phase 1 | |
| Completed |
NCT05800249 -
PE0116 Injection in Treatment of Patients With Advanced Solid Tumours
|
Phase 1 | |
| Active, not recruiting |
NCT04294576 -
Safety Study of BJ-001, an IL-15 Fusion Protein, for Locally Advanced/Metastatic Solid Tumors
|
Phase 1 |